Pathologic Complete Response to Neoadjuvant Imatinib of a Gastric Stromal Tumor with Concomitant Mutations in : A Case Report and Literature Review

Overview

Journal Clin Case Rep

Date 2023 Jun 12

PMID 37305871

Authors

Mariem Ben Rekaya

Feryel Ksontini

Linda Bel Haj Kacem

Farah Sassi

Emna Harigua-Souiai

Ryma Boujneh

Ahmed Hmayada

Yosra Zaimi

Mouna Ayadi

Mediha Trabelsi

Ridha Mrad

Soumaya Rammeh

Affiliations

Soon will be listed here.

Abstract

Key Clinical Message: We report the first case of pathologic complete response (pCR) to neoadjuvant imatinib in a gastric stromal tumor harboring mutations in both exons 11 and 9. The significance of this co-occurrence is unknown and might increase the responsiveness of gastrointestinal stromal tumors (GISTs) to imatinib.

Abstract: pCR of GIST to neoadjuvant imatinib is rare. We report a case of pCR to neoadjuvant imatinib in a gastric stromal tumor that harbored co-occurrence of multiple mutations in exons 11 and 9. This co-occurrence in exons 9 and 11 is the first to be reported in the English literature.

Citing Articles

Pathologic complete response to neoadjuvant imatinib of a gastric stromal tumor with concomitant mutations in : A case report and literature review.

Ben Rekaya M, Ksontini F, Bel Haj Kacem L, Sassi F, Harigua-Souiai E, Boujneh R Clin Case Rep. 2023; 11(6):e7463.

PMID: 37305871 PMC: 10248213. DOI: 10.1002/ccr3.7463.

References

Braggio E, Braggio D, Small I, Lopes L, Valadao M, Gouveia M . Prognostic relevance of KIT and PDGFRA mutations in gastrointestinal stromal tumors. Anticancer Res. 2010; 30(6):2407-14. View

Lasota J, Kowalik A, Felisiak-Golabek A, Zieba S, Waloszczyk P, Masiuk M . Primary malignant melanoma of esophagus: clinicopathologic characterization of 20 cases including molecular genetic profiling of 15 tumors. Mod Pathol. 2019; 32(7):957-966. PMC: 8210848. DOI: 10.1038/s41379-018-0163-y. View

Li Y, Chen X, Ma X, Lu X . Computed tomography in the size measurement of gastric gastrointestinal stromal tumors: Implication to risk stratification and "wait-and-see" tactics. Eur J Surg Oncol. 2022; 48(8):1739-1745. DOI: 10.1016/j.ejso.2022.01.007. View

Bonvalot S, Eldweny H, Le Pechoux C, Vanel D, Terrier P, Cavalcanti A . Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era. Ann Surg Oncol. 2006; 13(12):1596-603. DOI: 10.1245/s10434-006-9047-3. View

Desai J . Response assessment in gastrointestinal stromal tumor. Int J Cancer. 2010; 128(6):1251-8. DOI: 10.1002/ijc.25729. View

Yoh K, Nishiwaki Y, Ishii G, Goto K, Kubota K, Ohmatsu H . Mutational status of EGFR and KIT in thymoma and thymic carcinoma. Lung Cancer. 2008; 62(3):316-20. DOI: 10.1016/j.lungcan.2008.03.013. View

Hussain S, Babu S, Naqvi H, Singh P, Mahdi F . The Frequency of Mutations in Exon 11 of the c-kit Gene in Patients With Leukemia. Turk J Haematol. 2014; 29(1):10-6. PMC: 3986761. DOI: 10.5505/tjh.2012.60320. View

Mearadji A, den Bakker M, van Geel A, Eggermont A, Sleijfer S, Verweij J . Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis. Anticancer Drugs. 2008; 19(6):607-12. DOI: 10.1097/CAD.0b013e32830138f9. View

Mei L, Smith S, Faber A, Trent J, Grossman S, Stratakis C . Gastrointestinal Stromal Tumors: The GIST of Precision Medicine. Trends Cancer. 2018; 4(1):74-91. DOI: 10.1016/j.trecan.2017.11.006. View

10.

Kee D, Zalcberg J . Current and emerging strategies for the management of imatinib-refractory advanced gastrointestinal stromal tumors. Ther Adv Med Oncol. 2012; 4(5):255-70. PMC: 3424497. DOI: 10.1177/1758834012450935. View

11.

Ben Rekaya M, Ksontini F, Bel Haj Kacem L, Sassi F, Harigua-Souiai E, Boujneh R . Pathologic complete response to neoadjuvant imatinib of a gastric stromal tumor with concomitant mutations in : A case report and literature review. Clin Case Rep. 2023; 11(6):e7463. PMC: 10248213. DOI: 10.1002/ccr3.7463. View

12.

Antonescu C, Besmer P, Guo T, Arkun K, Hom G, Koryotowski B . Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res. 2005; 11(11):4182-90. DOI: 10.1158/1078-0432.CCR-04-2245. View

13.

Rediti M, Pellegrini E, Molinara E, Cerullo C, Fonte C, Lunghi A . Complete pathological response in advanced extra-gastrointestinal stromal tumor after imatinib mesylate therapy: a case report. Anticancer Res. 2014; 34(2):905-7. View

14.

Astolfi A, Indio V, Nannini M, Saponara M, Schipani A, De Leo A . Targeted Deep Sequencing Uncovers Cryptic KIT Mutations in KIT/PDGFRA/SDH/RAS-P Wild-Type GIST. Front Oncol. 2020; 10:504. PMC: 7188756. DOI: 10.3389/fonc.2020.00504. View

15.

Cheng C, Tsai C, Yeh C, Chiang K, Chen Y, Wang S . Clinical significance of pathological complete response in patients with metastatic gastrointestinal stromal tumors after imatinib mesylate treatment--lessons learned. Anticancer Res. 2014; 34(11):6617-25. View

16.

Mandala M, Pezzica E, Tamborini E, Guerra U, Lagonigro S, Forloni B . Neoadjuvant imatinib in a locally advanced gastrointestinal stromal tumour (GIST) of the rectum: a rare case of two GISTs within a family without a familial GIST syndrome. Eur J Gastroenterol Hepatol. 2007; 19(8):711-3. DOI: 10.1097/01.meg.0000230087.83792.1f. View

17.

Chacon M, Roca E, Huertas E, Loria F, Domenechini E . CASE 3. Pathologic complete remission of metastatic gastrointestinal stromal tumor after imatinib mesylate. J Clin Oncol. 2005; 23(7):1580-2. DOI: 10.1200/JCO.2005.03.194. View

18.

Agaram N, Wong G, Guo T, Maki R, Singer S, DeMatteo R . Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer. 2008; 47(10):853-9. PMC: 2902874. DOI: 10.1002/gcc.20589. View

19.

Incorvaia L, Fanale D, Vincenzi B, De Luca I, Bartolotta T, Cannella R . Type and Gene Location of Mutations Predict Progression-Free Survival to First-Line Imatinib in Gastrointestinal Stromal Tumors: A Look into the Exon. Cancers (Basel). 2021; 13(5). PMC: 7956844. DOI: 10.3390/cancers13050993. View

20.

Scaife C, Hunt K, Patel S, Benjamin R, Burgess M, Chen L . Is there a role for surgery in patients with "unresectable" cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate?. Am J Surg. 2003; 186(6):665-9. DOI: 10.1016/j.amjsurg.2003.08.023. View